Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

3000-03-005/ENGOT-OV44/ The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY AS FIRST-LINETREATMENT OF STAGE III OR IV NONMUCINOUS EPITHELIAL OVARIAN CANCER
Study of TSR-042 and Niraparib in Treatment of Stage III or IV Epithelial Ovarian Cancer
Sponsor:TESARO, Inc.
Enrolling:Female Patients Only
IRB Number:AAAS0882
U.S. Government ID:NCT03602859
Contact: Reena Vattakalam: 212-342-6895 / rmv2110@cumc.columbia.edu
Additional Study Information:

This study is being done to determine if adding the investigational drugs (TSR-042 and niraparib) to standard of care treatment delays or prevents ovarian cancer recurrence (prevents the ovarian cancer from coming back).

Do You Qualify?
Have you been diagnosed with epithelial ovarian cancer?YesNo
Do you have State III or IV ovarian cancer?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Reena Vattakalam
Email: rmv2110@cumc.columbia.edu
Phone: 212-342-6895